Bristol Myers Squibb

Our scientists are collaborating with Johnson & Johnson Innovative Medicine to find new ways to improve the risk-benefit profile in treatment of thrombotic events for more patients. Together, our combined dedication to advance cardiovascular care continues to power our Phase 3 Librexia program. As we join our industry peers at #ACC25, our Factor XIa research is a key focus. Learn more about our efforts: https://bit.ly/41Yz7Tz

At #SIRS2025, we’re presenting our latest findings in #schizophrenia research. Explore how we are developing innovative treatments to address the complex needs of people living with serious mental health conditions. This is part of our ongoing commitment to advancing research in #neuroscience. Learn more: https://bit.ly/4iSLWoq #OneBMS

“We need to learn to be a future-ready workforce.” See memorable moments from our immersive #WomensHistoryMonth Keynote Session, including a conversation about building resilience and high-performing teams in the age of AI, hosted by the BMS Network of Women (B-NOW) Global Lead Carla Daily with Lynelle Hoch, President, Cell Therapy Organization, Sydney Klein, Chief Information Security Officer, and Amanda Poole, Chief People Officer, plus a keynote by teamwork expert Erica Dhawan. Join us in celebrating our female colleagues who are fueling innovation for patients and our allies who foster a supportive and empowering environment for all women at BMS. #OneBMS

With a 70-year legacy in #CardiovascularDisease (CVD) research, our philosophy has always been to help improve the lives of patients living with cardiovascular conditions. At #ACC25, we’re presenting new real-world and clinical data on our research in symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Explore how we’re working to advance care for those living with CVD: https://bit.ly/43zIdY5

We're looking forward to the ACC Congress and sharing the latest information about clinical data in obstructive hypertrophic cardiomyopathy. Learn more about the HCM disease spectrum: https://bit.ly/4hSAx6p #ACC2025

This #WomensHistoryMonth, we're excited to share that the Healthcare Businesswomen’s Association named our colleagues Carla Daily, Meera Patturajan and Lynn Kubinski as 2025 Luminaries and Tamara McCulloch as a 2025 Rising Star for their impact in advancing the role of women in healthcare. #OneBMS Learn more about our #HBAWOTY25 honorees: https://bit.ly/4c7xt5n

Multiple myeloma remains a persistent, incurable disease that significantly impacts patients’ quality of life, highlighting the urgent need for novel treatments. This #MyelomaACTIONMonth, Florencia Davel, Rosanna Ricafort and Ridwaan Jhetam discuss the many ways we are taking action aimed at transforming the multiple myeloma treatment paradigm to improve outcomes for patients. #DecodedByBMS #OneBMS 

A combination of the right team, mentors and leaders motivates drug discovery researchers like Ari to keep pushing the boundaries of science. See how our innovative culture drives transformative science: https://bit.ly/4hY6TO9 #OneBMS

To target disease-causing proteins, previously considered “undruggable,” our scientists are investigating three different modalities for targeted protein degradation. Harnessing this three-pronged approach provides more opportunities for breakthroughs that may offer meaningful new options for a broad range of patients, including those living with #MultipleMyeloma. See how we’re fighting disease-causing proteins with molecular glues: https://bit.ly/4gXnX5y #MyelomaActionMonth #OneBMS